Evaluation of a laboratory-based high-throughput SARS-CoV-2 antigen assay

June 14, 2022

Sebastian Hörber 1, Christoph Drees 1, Tina Ganzenmueller 2, Kristina Schmauder 3, Silke Peter 3, Dirk Biskup 4, Andreas Peter 1

Abstract

Objectives: Antigen tests are an essential part of SARS-CoV-2 testing strategies. Rapid antigen tests are easy to use but less sensitive compared to nucleic acid amplification tests (NAT) and less suitable for large-scale testing. In contrast, laboratory-based antigen tests are suitable for high-throughput immunoanalyzers. Here we evaluated the diagnostic performance of the laboratory-based Siemens Healthineers SARS-CoV-2 Antigen (CoV2Ag) assay.

Methods: In a public test center, from 447 individuals anterior nasal swab specimens as well as nasopharyngeal swab specimens were collected. The nasal swab specimens were collected in sample inactivation medium and measured using the CoV2Ag assay. The nasopharyngeal swab specimens were measured by RT-PCR. Additionally, 9,046 swab specimens obtained for screening purposes in a tertiary care hospital were analyzed and positive CoV2Ag results confirmed by NAT.

Results: In total, 234/447 (52.3%) participants of the public test center were positive for SARS-CoV-2-RNA. Viral lineage B1.1.529 was dominant during the study. Sensitivity and specificity of the CoV2Ag assay were 88.5% (95%CI: 83.7-91.9%) and 99.5% (97.4-99.9%), respectively. Sensitivity increased to 93.7% (97.4-99.9%) and 98.7% (97.4-99.9%) for swab specimens with cycle threshold values <30 and <25, respectively. Out of 9,046 CoV2Ag screening tests from hospitalized patients, 21 (0.2%) swab specimens were determined as false-positive by confirmatory NAT.

Conclusions: Using sample tubes containing inactivation medium the laboratory-based high-throughput CoV2Ag assay is a very specific and highly sensitive assay for detection of SARS-CoV-2 antigen in nasal swab specimens including the B1.1.529 variant. In low prevalence settings confirmation of positive CoV2Ag results by SARS-CoV-2-RNA testing is recommended.

Keywords: COVID-19; SARS-CoV-2 antigen; anterior nasal swab; high-throughput; laboratory-based.

  1. Institute for Clinical Chemistry and Pathobiochemistry, Department for Diagnostic Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany.
  2. Institute of Medical Virology, Department for Diagnostic Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany.
  3. Institute of Medical Microbiology and Hygiene, Department for Diagnostic Laboratory Medicine, University Hospital Tübingen, Tübingen, Germany.
  4. CeGaT GmbH, Tübingen, Germany.